Tara C. Mitchell

13.0k total citations · 3 hit papers
60 papers, 3.9k citations indexed

About

Tara C. Mitchell is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Tara C. Mitchell has authored 60 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 18 papers in Molecular Biology and 17 papers in Immunology. Recurrent topics in Tara C. Mitchell's work include Cancer Immunotherapy and Biomarkers (40 papers), CAR-T cell therapy research (22 papers) and Immunotherapy and Immune Responses (15 papers). Tara C. Mitchell is often cited by papers focused on Cancer Immunotherapy and Biomarkers (40 papers), CAR-T cell therapy research (22 papers) and Immunotherapy and Immune Responses (15 papers). Tara C. Mitchell collaborates with scholars based in United States, Australia and France. Tara C. Mitchell's co-authors include Omid Hamid, Caroline Robert, Janet Maleski, Thomas F. Gajewski, Lynn M. Schuchter, Giorgos C. Karakousis, Alexander C. Huang, Ravi K. Amaravadi, Xiaowei Xu and Georgina V. Long and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Immunity.

In The Last Decade

Tara C. Mitchell

54 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

2019 703 citations Georgina V. Long, Reinhard Dummer et al. The Lancet Oncology profile →
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

2019 638 citations Omid Hamid, Caroline Robert et al. Annals of Oncology profile →
Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms

2020 598 citations Sasikanth Manne, Shin Foong Ngiow et al. profile →

Peers

Tara C. Mitchell

ONCOL

IMMUN

PRM

Hatem Soliman United States

Anthony J. Olszanski United States

Scott J. Diede United States

Nicolas van Baren Belgium

Mahua Dey United States

Emanuela Romano France

Wim H.J. Kruit Netherlands

Jean‐François Baurain Belgium

Catherine Lévy United States

Laïla‐Aïcha Hanafi United States

Hatem Soliman United States

Tara C. Mitchell

1.9k ×0.7

ONCOL

1.2k ×0.7

IMMUN

780 ×0.8

675 ×0.9

PRM

362 ×1.0

Citations per year, relative to Tara C. Mitchell Tara C. Mitchell (= 1×) peers Hatem Soliman

Countries citing papers authored by Tara C. Mitchell

Since Specialization

Citations

This map shows the geographic impact of Tara C. Mitchell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tara C. Mitchell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tara C. Mitchell more than expected).

Fields of papers citing papers by Tara C. Mitchell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tara C. Mitchell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tara C. Mitchell. The network helps show where Tara C. Mitchell may publish in the future.

Co-authorship network of co-authors of Tara C. Mitchell

This figure shows the co-authorship network connecting the top 25 collaborators of Tara C. Mitchell. A scholar is included among the top collaborators of Tara C. Mitchell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tara C. Mitchell. Tara C. Mitchell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mitchell, Tara C., David E. Elder, Phyllis A. Gimotty, et al.. (2024). Tumor-Infiltrating Lymphocytes in Necrotic Tumors after Melanoma Neoadjuvant Anti–PD-1 Therapy Correlate with Pathologic Response and Recurrence-Free Survival. Clinical Cancer Research. 30(21). 4987–4994. 1 indexed citations

Huang, Alexander C., Xiaowei Xu, Rosemarie Mick, et al.. (2024). FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma. Clinical Cancer Research. 30(9). 1758–1767. 10 indexed citations

Abbott, James, Sarah Ahmed, Melissa Wilson, et al.. (2024). Inherited Basaloid Neoplasms Associated With SUFU Pathogenic Variants. JAMA Dermatology. 160(11). 1220–1220.

Anstadt, Emily J., Brian Chu, Nikhil Yegya‐Raman, et al.. (2022). Moderate Colitis Not Requiring Intravenous Steroids Is Associated with Improved Survival in Stage IV Melanoma after Anti-CTLA4 Monotherapy, But Not Combination Therapy. The Oncologist. 27(9). 799–808. 4 indexed citations

Zhang, Wei, Wenqun Zhong, Beike Wang, et al.. (2022). ICAM-1-mediated adhesion is a prerequisite for exosome-induced T cell suppression. Developmental Cell. 57(3). 329–343.e7. 106 indexed citations

Karakousis, Giorgos C. & Tara C. Mitchell. (2022). Personalizing the approach to neoadjuvant therapy: a promising path to improving outcomes of resectable melanoma. Nature Reviews Clinical Oncology. 19(11). 679–680. 1 indexed citations

Cutsem, Eric Van, Hans Prenen, Kristen Spencer, et al.. (2021). 529 Phase 1 study of INCB086550, an oral PD-L1 inhibitor, in immune-checkpoint naive patients with advanced solid tumors. SHILAP Revista de lepidopterología. A559–A560. 11 indexed citations

Hamid, Omid, Caroline Robert, Adil Daud, et al.. (2021). Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. European Journal of Cancer. 157. 391–402. 19 indexed citations

McLane, Laura M., Shin Foong Ngiow, Zeyu Chen, et al.. (2021). Role of nuclear localization in the regulation and function of T-bet and Eomes in exhausted CD8 T cells. Cell Reports. 35(6). 109120–109120. 77 indexed citations

10.

Maity, Amit, Rosemarie Mick, Ramesh Rengan, et al.. (2021). A stratified phase I dose escalation trial of hypofractionated radiotherapy followed by ipilimumab in metastatic melanoma: long-term follow-up and final outcomes. OncoImmunology. 10(1). 1863631–1863631. 18 indexed citations

11.

Piha‐Paul, Sarina A., Tara C. Mitchell, Solmaz Sahebjam, et al.. (2020). 419 Pharmacodynamic biomarkers demonstrate T-cell activation in patients treated with the oral PD-L1 inhibitor INCB086550 in a phase 1 clinical trial. Regular and Young Investigator Award Abstracts. A255–A255. 3 indexed citations

12.

Mohiuddin, Jahan J., Brian Chu, Andrea Facciabene, et al.. (2020). Association of Antibiotic Exposure With Survival and Toxicity in Patients With Melanoma Receiving Immunotherapy. JNCI Journal of the National Cancer Institute. 113(2). 162–170. 96 indexed citations

13.

Luo, Leo Y., Mark H. O’Hara, Tara C. Mitchell, et al.. (2020). Combining Radiation with Immunotherapy: The University of Pennsylvania Experience. Seminars in Radiation Oncology. 30(2). 173–180. 8 indexed citations

14.

Hamid, Omid, Anthony M. Joshua, Antoni Ribas, et al.. (2020). 1139P Long-term safety profile of pembrolizumab monotherapy and relationship with clinical outcome: A pooled analysis of patients with advanced melanoma. Annals of Oncology. 31. S762–S763. 2 indexed citations

15.

Sanseviero, Emilio, Erin M. O’Brien, Tamer B. Shabaneh, et al.. (2019). Anti–CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control. Cancer Immunology Research. 7(8). 1371–1380. 51 indexed citations

16.

Long, Georgina V., Reinhard Dummer, Omid Hamid, et al.. (2019). Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. The Lancet Oncology. 20(8). 1083–1097. 703 indexed citations breakdown →

17.

Menzies, Alexander M., Elisa A. Rozeman, Rodabe Navroze Amaria, et al.. (2019). Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).. Journal of Clinical Oncology. 37(15_suppl). 9503–9503. 63 indexed citations

18.

Villaruz, Liza C., Bryan J. Schneider, Todd M. Bauer, et al.. (2018). OA05.02 Epacadostat Plus Pembrolizumab in Patients with Non-Small Cell Lung Cancer: Phase 1/2 Results from ECHO-202/KEYNOTE-037. Journal of Thoracic Oncology. 13(10). S330–S330. 3 indexed citations

19.

Maity, Amit, Rosemarie Mick, Alexander C. Huang, et al.. (2018). A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours. British Journal of Cancer. 119(10). 1200–1207. 79 indexed citations

20.

Call, Mindy K., et al.. (2003). Relationship among Location of T-Antigen-Induced DNA Distortion, Auxiliary Sequences, and DNA Replication Efficiency. Journal of Virology. 77(19). 10651–10657. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact